Notably, a cohort of melanoma patients undergoing sequential anti-CTLA4 and anti-PD-1 had a survival advantage over both the corresponding monotherapies or the anti-PD-1 followed by anti-CTLA4 (Eschweiler et al., 2021). Here, CTLA4 is linked to melanoma.